亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Efficacy and Safety of Roxadustat for Anemia in Patients Receiving Chemotherapy for Nonmyeloid Malignancies: A Randomized, Open-Label, Active-Controlled Phase III Study

医学 贫血 促红细胞生成素 内科学 化疗 胃肠病学 血红蛋白 剂量 临床终点 不利影响 随机对照试验 外科
作者
Shun Lü,Jiong Wu,Jiang Jin,Qisen Guo,Yan Yu,Yu Liu,Qian Zhang,Ling Qian,Xiumei Dai,Yanyan Xie,Ting Fu,Tyson Lee,Yan Lu,Rui Ma,Mark D. Eisner
出处
期刊:Journal of Clinical Oncology [American Society of Clinical Oncology]
被引量:1
标识
DOI:10.1200/jco.23.02742
摘要

PURPOSE We evaluated the efficacy and safety of roxadustat, a first-in-class hypoxia-inducible factor prolyl hydroxylase inhibitor, for chemotherapy-induced anemia (CIA) in patients with nonmyeloid malignancies receiving multicycle treatments of chemotherapy. PATIENTS AND METHODS In this open-label, noninferiority phase III study conducted at 44 sites in China, 159 participants age ≥18 years with CIA nonmyeloid malignancy and CIA were randomly assigned (1:1) to oral roxadustat or subcutaneous recombinant human erythropoietin-α (rHuEPO-α) three times a week for 12 weeks. Roxadustat starting dosages were 100, 120, and 150 mg three times a week for participants weighing 40-<50, 50-60, and >60 kg, respectively. rHuEPO-α starting dosage for all participants was 150 IU/kg three times a week. Both roxadustat and rHuEPO-α dosages could be modified. The primary end point was least-squares mean (LSM) change in hemoglobin (Hb) concentration from baseline to the concentration averaged over weeks 9-13. RESULTS Of the 159 participants randomly assigned, 140 were included in the per-protocol set (roxadustat, n = 78; rHuEPO-α, n = 62). The LSM (95% two-sided CI) change from baseline to weeks 9-13 in Hb concentration was 17.1 (13.58 to 20.71) g/L with roxadustat and 15.4 (11.34 to 19.50) g/L with rHuEPO-α (mean difference [95% CI], 1.7 [–3.39 to 6.84]). The lower bound of the one-sided 97.5% CI for the treatment difference (‒3.4 g/L) was greater than the predefined noninferiority margin of ‒6.6 g/L, establishing noninferiority. Noninferiority was supported by five of six key secondary end points. Rates of adverse events were generally comparable between treatments and consistent with previous findings. CONCLUSION Roxadustat was noninferior to rHuEPO-α in treating CIA in participants with nonmyeloid malignancies receiving multicycle treatments of myelosuppressive chemotherapy. The oral formulation of roxadustat may potentially increase compliance.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
慕青应助dihaha采纳,获得10
1秒前
烟花应助Leo采纳,获得10
11秒前
dihaha完成签到,获得积分10
11秒前
Herbs完成签到 ,获得积分10
16秒前
FashionBoy应助dihaha采纳,获得10
19秒前
zqq完成签到,获得积分0
26秒前
脑洞疼应助十三采纳,获得10
31秒前
192724836完成签到,获得积分20
37秒前
小锤发布了新的文献求助10
42秒前
含蓄的寄翠完成签到,获得积分10
44秒前
科研通AI2S应助192724836采纳,获得10
56秒前
tinyliiyong完成签到,获得积分10
1分钟前
1分钟前
sss完成签到 ,获得积分10
1分钟前
小锤完成签到 ,获得积分20
1分钟前
李爱国应助科研通管家采纳,获得10
1分钟前
1分钟前
1分钟前
彭于晏应助十三采纳,获得10
1分钟前
布同完成签到,获得积分10
1分钟前
1分钟前
林思完成签到,获得积分10
1分钟前
老王家的二姑娘完成签到 ,获得积分10
1分钟前
平常的长颈鹿完成签到,获得积分10
2分钟前
852应助平常的长颈鹿采纳,获得10
2分钟前
2分钟前
FashionBoy应助KSung采纳,获得10
2分钟前
2分钟前
小胖子发布了新的文献求助10
2分钟前
机灵自中发布了新的文献求助50
2分钟前
机灵自中完成签到,获得积分10
2分钟前
2分钟前
动人的笑白完成签到,获得积分20
2分钟前
KSung发布了新的文献求助10
2分钟前
2分钟前
2分钟前
zhaosheng发布了新的文献求助10
2分钟前
斯文败类应助zhaosheng采纳,获得10
3分钟前
远道发布了新的文献求助30
3分钟前
jwj完成签到 ,获得积分10
3分钟前
高分求助中
Sustainability in ’Tides Chemistry 2000
Studien zur Ideengeschichte der Gesetzgebung 1000
The ACS Guide to Scholarly Communication 1000
TM 5-855-1(Fundamentals of protective design for conventional weapons) 1000
Handbook of the Mammals of the World – Volume 3: Primates 805
Ethnicities: Media, Health, and Coping 800
Gerard de Lairesse : an artist between stage and studio 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3072598
求助须知:如何正确求助?哪些是违规求助? 2726326
关于积分的说明 7493683
捐赠科研通 2374098
什么是DOI,文献DOI怎么找? 1258887
科研通“疑难数据库(出版商)”最低求助积分说明 610394
版权声明 596983